Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis

Camille M Powers; Andrew K Yang; Hannah Verma; Jeremy Orloff; Austin J Piontkowski; Nicholas Gulati

doi:10.2196/53792

Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis

JMIR Dermatol. 2024 May 2:7:e53792. doi: 10.2196/53792.

Authors

Camille M Powers¹, Andrew K Yang¹, Hannah Verma¹, Jeremy Orloff¹, Austin J Piontkowski¹, Nicholas Gulati¹

Affiliation

¹ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

PMID: 38696235
PMCID: PMC11099803
DOI: 10.2196/53792

No abstract available

Keywords: cutaneous immune-related adverse event; immune checkpoint inhibitor; immunotherapy; medical dermatology; nivolumab; oncology; pembrolizumab; sentiment analysis.

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Antineoplastic Agents, Immunological / adverse effects
Attitude
Humans
Nivolumab* / adverse effects

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Nivolumab
pembrolizumab